Chidambaram R, Terunuma H, Balamurugan M, Dedeepiya V, Sumana P, Senthilkumar R, Rajmohan M, Karthick R, Preethy S, Abraham S. Cell based immunotherapy in a stage IIIA inflammatory breast cancer with declining innate immunity following successive chemotherapies; A case report. Molecular and Clinical Oncology (In print).

Preethy S, Dedeepiya V, Senthilkumar R, Rajmohan M, Karthick R, Terunuma H, Abraham S. Natural killer cells as a promising tool to tackle cancer—A review of sources, methodologies, and potentials. International Reviews of Immunology 2017(In print).

87. Bhamare S, Prabhakar P,Dharmadhikari A, Dedeepiya V, Terunuma H, Senthilkumar R, Srinivasan T, Reena HC, Preethy S, Abraham S. Autologous Immune Enhancement Therapy (AIET) in a case of Gall bladder cancer stage IV after surgical resection and chemotherapy yielding a stable non-progressive disease. J Cancer Res Ther. 2014 Jul-Sep;10(3):752-4.

86. Baskar S, Dedeepiya V D, Terunuma H, Manjunath S R, Senthilkumar R, Sivaraman G, Pandian A, Abraham S. Prolonged survival of a patient with inoperable, locally advanced adenocarcinoma of pancreas after autologous immune enhancement therapy with chemotherapy. Indian J Cancer 2015;52:395-6.

85. Revathi Raj, Deenadayalan M, Vimal Kumar G, Khandelwal V, Karuna Sri, Senthilkumar R, Abraham S, Hiroshi T. Autologous Immune Enhancement Therapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. Indian Journal of Hematology and Blood Transfusion.(epub)

84. Sumana P, Dedeepiya V, Terunuma H, Senthilkumar R, Srinivasan T, Reena HC, Preethy S, Abraham S. Cell based Autologous Immune Enhancement Therapy (AIET) after radiotherapy in a locally advanced carcinoma of the cervix. Case reports in Oncological Medicine. 2013 (2013), Article ID 903094,

83. Manjunath S, Ramanan G, Dedeepiya V, Terunuma H, Deng X, Baskar S, Senthilkumar R, Thamaraikannan P, Srinivasan T, Preethy S, Abraham S. Autologous immune enhancement therapy in recurrent ovarian cancer with metastases; 18 months follow-up- A case report. Case Rep Oncol 2012;5:114-118; posted online on Mar 2012

82. Kananathan R, Baskar S, Kohila K, Kirihara Y. Autologous Immune Enhancement Therapy (AIET): An approach towards cancer immunotherapy. 21st Asian Pacific Cancer Conference 10 - 12NOV2011.

81. Dedeepiya V, Terunuma H, Deng X, Baskar S, Manjunath S, Senthilkumar R, Murugan P, Thamaraikannan P, Srinivasan T, Preethy S, Abraham S. A comparative analysis of in vitro expansion of natural killer cells of a patient with autoimmune haemolytic anaemia and ovarian cancer with patients with other solid tumours.Oncology Letters. 2011;3(2). Doi: 10.3892/ol.2011.498; Posted online on Nov 29, 2011.

80. Abraham S, Ramanan G, Dedeepiya V, Manjunath S, Senthilkumar R, Murugan P, Srinivasan V, Thamaraikannan P, Tholcopiyan L, Srinivasan T, Preethy SP, Baskar S, Terunuma H. NK cell-based autologous immune enhancement therapy for advanced carcinoma of ovary – a case report. Cancer Immunotherapy and Immunomonitoring (CITIM) Conference; Budapest, Hungary; May2-5, 2011.

79. Abraham S, Manjunath S, Senthilkumar R, Murugan P, Srinivasan V, Thamaraikannan P, Tholcopiyan L, Srinivasan T, Preethy SP, Dedeepiya V, Terunuma H. Ex vivo expansion of clinical grade Natural Killer cells without feeder layers in stage III-IV cancer patients, post-chemotherapy and radiation. Cancer Immunotherapy and Immunomonitoring (CITIM) Conference; Budapest, Hungary; May2-5, 2011.

78. Cathelin D, Nicolas A, Bouchot A, Fraszczak J, Labb JR, Bonnotte B. Dendritic cell? tumor cell hybrids and immunotherapy: what's next? Cytotherapy. 2011 Feb 7.

77. Vauleon E, Avril T, Collet B, Mosser J, Quillien V. Overview of cellular immunotherapy for patients with glioblastoma. Clin Dev Immunol. 2010

76. Weng D, Song B, Durfee J, Sugiyama V, Wu Z, Koido S, Calderwood SK, Gong J. Induction of cytotoxic T lymphocytes against ovarian cancer-initiating cells. Int J Cancer. 2010

75. Tseng HC, Arasteh A, Paranjpe A, Teruel A, Yang W, Behel A, Alva JA, Walter G, Head C, Ishikawa TO, Herschman HR, Cacalano N, Pyle AD, Park NH, Jewett A. Increased lysis of stem cells but not their differentiated cells by natural killer cells; de-differentiation or reprogramming activates NK cells. PLoS One 2010.

74. Takada M, Terunuma H, Deng X, Dewan MZ, Saji S, Kuroi K, Yamamoto N, Toi M. Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach. Breast Cancer. 2010 Mar 31

73. Ahmed N, Salsman VS, Kew Y, Shaffer D, Powell S, Zhang YJ, Grossman RG, Heslop HE, Gottschalk S. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res. 2010 15;16(2):474-85

72. Berg M, Lundqvist A, McCoy P Jr, Samsel L, Fan Y, Tawab A, Childs R. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy. 2009;11(3):341-55.

71. Fujisaki H, Kakuda H, Shimasaki N, Imai C, Ma J, Lockey T, Eldridge P, Leung WH, Campana D. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res. 2009;69(9):4010-7.

70. Pietra G, Manzini C, Vitale M, Balsamo M, Ognio E, Boitano M, Queirolo P, Moretta L, Mingari MC. Natural killer cells kill human melanoma cells with characteristics of cancer stem cells. Int Immunol. 2009;21(7):793-801..

69. Stoeckle C, Gleske AK. Immunotherapy from basic research to clinical applications. Cancer Immunol Immunother. 2009;58(7):1129-36.

68. Dewan MZ, Takada M, Terunuma H, Deng X, Ahmed S, Yamamoto N, Toi M. Natural killer activity of peripheral-blood mononuclear cells in breast cancer patients. Biomed Pharmacother. 2009.

67. Castriconi R, Daga A, Dondero A, Zona G, Poliani PL, Melotti A, Griffero F, Marubbi D, Spaziante R, Bellora F, Moretta L, Moretta A, Corte G, Bottino C. NK cells recognize and kill human glioblastoma cells with stem cell-like properties.J Immunol. 2009 Mar 15;182(6):3530-9.

66. Cho D, Campana D. Expansion and activation of natural killer cells for cancer immunotherapy. Korean J Lab Med. 2009;29(2):89-96.

65. Sasaki K, Zhao X, Pardee AD, Ueda R, Fujita M, Sehra S, Kaplan MH, Kane LP, Okada H, Storkus WJ. Stat6 signaling suppresses VLA-4 expression by CD8+ T cells  and limits their ability to infiltrate tumor lesions in vivo. J Immunol. 2008 1;181(1):104-8.

64 Grzywacz B, Miller JS, Verneris MR. Use of natural killer cells as immunotherapy for leukaemia. Best Pract Res Clin Haematol. 2008 ;21(3):467-83.

63. Molling JW, Moreno M, van der Vliet HJ, van den Eertwegh AJ, Scheper RJ, von Blomberg BM, Bontkes HJ. Invariant natural killer T cells and immunotherapy of cancer. Clin Immunol. 2008;129(2):182-94.

62. Recchia F, Candeloro G, Di Staso M, Necozione S, Bisegna R, Bratta M, Tombolini V, Rea S. Maintenance immunotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck. J Immunother. 2008; 31(4):413-9.

61. Song W, van der Vliet HJ, Tai YT, Prabhala R, Wang R, Podar K, Catley L, Shammas MA, Anderson KC, Balk SP, Exley MA, Munshi NC. Generation of antitumor invariant natural killer T cell lines in multiple myeloma. Clin Cancer Res. 2008;14(21):6955-62.

60. Terme M, Ullrich E, Delahaye NF, Chaput N, Zitvogel L. Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat Immunol. 2008;9(5):486-94.

59. Fujii S. Exploiting dendritic cells and natural killer T cells in immunotherapy against malignancies. Trends Immunol. 2008;29(5):242-9.

58. Mitchell DA, Fecci PE, Sampson JH. Immunotherapy of malignant brain tumors. Immunol Rev. 2008 Apr;222:70-100.

57. Chan CJ, Andrews DM, Smyth MJ. Can NK cells be a therapeutic target in human cancer? Eur J Immunol. 2008; 38(11):2964-8.

56. Motohashi S, Nakayama T. Clinical applications of natural killer T cell-based immunotherapy for cancer. Cancer Sci. 2008; 99(4):638-45.

55 Recchia F, Sica G, Candeloro G, Necozione S, Bisegna R, Bratta M, Rea S. Maintenance immunotherapy in metastatic breast cancer. Oncol Rep. 2008;20(5):1173-9.

54. Srivastava S, Lundqvist A, Childs RW. Natural killer cell immunotherapy for cancer a new hope. Cytotherapy. 2008; 10(8):775-83.

53. Alici E, Sutlu T, Björkstrand B, Gilljam M, Stellan B, Nahi H, Quezada HC,Gahrton G, Ljunggren HG, Dilber MS. Autologous antitumor activity by NK cells expanded from myeloma patients using GMP compliant components. Blood. 2008;111(6):3155-62.

52. Copper LJ. Adoptive cellular immunotherapy for childhood malignancies. Bone Marrow Transplantation,2008: 41, 183–192.

51. Terunuma H, Deng X, Dewan Z, Fujimoto S, Yamamoto N. Potential role of NK cells in the induction of immune responses: implications for NK cell-based immunotherapy for cancers and viral infections. Int Rev Immunol. 2008;27(3):93-110.

50. Rosenberg SA. . Advances in Drug Development. Clinical Advances in Hematology & Oncology 2008.

49. Grupp SA, Verneris M, Sondel PM, Cooper LJ. Immunotherapy for pediatric cancer. Biol Blood Marrow Transplant. 2008;14(1 Suppl 1):33-43.

48. Gao JQ, Okada N, Mayumi T, Nakagawa S. Immune cell recruitment and cell-based system for cancer therapy. Pharm Res. 2008;25(4):752-68.

47. Sivaraman G, Pandian A,Baskar S, Senthil KR, Senthilnagarajan R, Dedeepiya V, Abraham S. Autologous Immune Enhancement therapy for advanced carcinoma of pancreas a case report. PASRM 2008-004.

46. Dewan MZ, Terunuma H, Takada M, Tanaka Y, Abe H, Sata T, Toi M, Yamamoto N. Role of natural killer cells in hormone-independent rapid tumor formation and spontaneous metastasis of breast cancer cells in vivo. Breast Cancer Res Treat. 2007;104(3):267-75.

45. Kim HM, Lim J, Park SK, Kang JS, Lee K, Lee CW, Lee KH, Yun MJ, Yang KH, Han G, Kwon SW, Kim Y, Han SB. Antitumor activity of cytokine-induced killer cells against human lung cancer. Int Immunopharmacol. 2007;7(13):1802-7.

44. Kim HM, Lim J, Yoon YD, Ahn JM, Kang JS, Lee K, Park SK, Jeong YJ, Kim JM, Han G, Yang KH, Kim YJ, Kim Y, Han SB. Anti-tumor activity of ex vivo expanded cytokine-induced killer cells against human hepatocellular carcinoma. Int Immunopharmacol. 2007;7(13):1793-801.

43. Terunuma H, Wada A, Deng X, Yasuma Y, Onishi T, Toki A, Abe H. Mild hyperthermia modulates the relative frequency of lymphocyte cell subpopulations: an increase in a cytolytic NK cell subset and a decrease in a regulatory T cell subset. Thermal Med. 2007; 23 (1).

42. McKenna DH Jr, Sumstad D, Bostrom N, Kadidlo DM, Fautsch S, McNearney S, Dewaard R, McGlave PB, Weisdorf DJ, Wagner JE, McCullough J, Miller JS.Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience. Transfusion. 2007;47(3):520-8.

41. Strohlein MA , Heiss MM. Immunotherapy of Peritoneal Carcinomatosis. Peritoneal Carcinomatosis 2007.

40. Sasaki K, Zhu X, Vasquez C, Nishimura F, Dusak JE, Huang J, Fujita M, Wesa A, Potter DM, Walker PR, et al. Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors. Cancer Res 2007;67:6451–6458.

39. Ljunggren HG, Malmberg KJ. Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol. 2007;7(5):329-39.

38. Zamai L, Ponti C, Mirandola P, Gobbi G, Papa S, Galeotti L, Cocco L, Vitale M. NK cells and cancer. J Immunol. 2007 ;178(7):4011-6.

37. Stagg J, Smyth MJ. NK cell-based cancer immunotherapy. Drug News Perspect. 2007;20(3):155-63.

36. Arina A, Murillo O, Dubrot J, Azpilikueta A, Alfaro C, Perez-Gracia JL, Bendandi M, Palencia B, Hervás-Stubbs S, Melero I. Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer. Expert Opin Biol Ther. 2007 ;7(5):599-615.

35. Recchia F, Saggio G, Candeloro G, Cesta A, Amiconi G, Blasio AD, Necozione S, Rea S. Chemoimmunotherapy in the treatment of metastatic gastric cancer. Anticancer Drugs. 2007;18(5):597-604.

34. Barrett AJ, Sharp JG. Commentry- Cytotoxic lymphocytes for clinic. Cytotherapy 2006; 8 (2): 93-9.

33. Damodar S, Terunuma H , Sheriff AK , Farzana L , Manjunath S , Senthilkumar R , Shastikumar G , Abraham S , Wang FS. Autologous Immune Enhancement Therapy (AIET) for a Case of Acute Myeloid Leukemia (AML) - Our Experience. PASRM 2006-001.

32. Dewan MZ, Terunuma H, Toi M, Tanaka Y, Katano H, Deng X, Abe H, Nakasone T, Mori N, Sata T, Yamamoto N. Potential role of natural killer cells in controlling growth and infiltration of AIDS-associated primary effusion lymphoma cells. Cancer Sci. 2006;97(12):1381-7.

31. Nishimura F, Dusak JE, Eguchi J, Zhu X, Gambotto A, Storkus WJ, Okada H. Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN inducible protein-10. Cancer Res 2006;66:4478–4487.

30. Polyak K, Hahn WC. Roots and stems: stem cells in cancer. Nat Med. 2006;12(3):296-300.

29. Rosenberg SA. Cell transfer and other immunotherapeutic strategies. Clin Adv Hematol Oncol. 2005;3(1):28-9.

28. Kaneko T, Goto S, Kato A, Akeyama A, Tomonaga M, Fujimoto K, Miyamoto Y, Eriguchi M, Egawa K. Efficacy of immuno-cell therapy in patients with advanced pancreatic cancer. Anticancer Res. 2005;25(6A):3709-14.

27. Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Haworth LR, Levy C, Kleiner D, Mavroukakis SA, Yellin M, Rosenberg SA. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol. 2005;12(12):1005-16.

26. Rosenberg SA. Cancer immunotherapy comes of age. Nat Clin Pract Oncol. 2005;2(3):115.

25. Dewan MZ, Terunuma H, Ahmed S, Ohba K, Takada M, Tanaka Y, Toi M, Yamamoto N. Natural killer cells in breast cancer cell growth and metastasis in SCID mice. Biomed Pharmacother. 2005.

24. Goto S, Kaneko T, Miyamoto Y, Eriguchi M, Kato A, Akeyama T, Fujimoto K, Tomonaga M, Egawa K. Combined immunocell therapy using activated lymphocytes and monocyte-derived dendritic cells for malignant melanoma. Anticancer Res. 2005;25(6A):3741-6.

23. Ishikawa E, Tsuboi K, Saijo K, Harada H, Takano S, Nose T, Ohno T. Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res. 2004;24(3b):1861-71.

22. Shi M , Zhang B , Tang ZR , Lei ZY , Wang HF , Feng YY , Fan ZP , Xu DP , Wang FS . Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma. World J Gastroenterol. 2004;10(8):1146-51

21. Peng BG, Liang LJ, He Q, Huang JF, Lu MD. Expansion and activation of natural killer cells from PBMC for immunotherapy of hepatocellular carcinoma. World J Gastroenterol. 2004;10(14):2119-23.

20. Rosenberg SA. Development of effective immunotherapy for the treatment of patients with cancer. J Am Coll Surg. 2004;198(5):685-96.

19. Rosenberg SA. Shedding light on immunotherapy for cancer. N Engl J Med. 2004 ;350(14):1461-3.

18. Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci U S A. 2004;101.

17. Kaneko T, Goto S, Kushima Y, Miyamoto Y, Eriguchi M, Nieda M, Egawa K. A report of three patients treated with immunocell therapy with imatinib mesylate. Anticancer Res. 2004;24(5C):3303-9.

16. Egawa K. Immuno-cell therapy of cancer in Japan. Anticancer Res. 2004;24(5C):3321-6.

15. Oikawa T, Kawai K, Ishiwata I, Ohno T, Akaza H. Induction of potent antitumour natural-killer cells from peripheral blood of patients with advanced prostate cancer. BJU Int. 2003 ;92(9):1009-15.

14. Dudley ME, Rosenberg SA.Adoptive-cell-transfer therapy for the treatment of patients with cancerNat Rev Cancer. 2003;3(9):666-75.

13. Yang Q, Hokland ME, Bryant JL, Zhang Y, Nannmark U, Watkins SC, Goldfarb RH, Herberman RB, Basse PH. Tumor-localization by adoptively transferred, interleukin-2-activated NK cells leads to destruction of well-established lung metastases. Int J Cancer. 2003;105(4):512-9.

12. Kono K, Takahashi A, Ichihara F, Amemiya H, Iizuka H, Fujii H, Sekikawa T, Matsumoto Y. Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial. Clin Cancer Res. 2002;8(6):1767-71.

11. Wang FS , Liu MX , Zhang B , Shi M , Lei ZY , Sun WB , Du QY , Chen JM . Antitumor activities of human autologous cytokine-induced killer (CIK) cells against hepatocellular carcinoma cells in vitro and in vivo. World J Gastroenterol. 2002 ;8(3):464-8.

10. Ashihara E, Shimazaki C, Okano A, Hatsuse M, Okamoto A, Shimura K, Takahashi R, Sumikuma T, Inaba T, Fujita N, Murakami S, Haruyama H, Nakagawa M. Infusion of a high number of CD34+ cells provides a rapid hematopoietic recovery and cost savings in autologous peripheral blood stem cell transplantation. Jpn J Clin Oncol. 2002;32(4):135-9.

9. Goto S, Shirotani N, Hatakeyama M, Tagami C, Arakawa H, Kuwata E, Noguchi K, Egawa K. Clinical benefit of non-toxic therapy in patients with advanced cancer (opinion). Anticancer Res. 2002 ;22(4):2461-4.

8. Schleuning M. Adoptive allogeneic immunotherapy--history and future perspectives. Transfus Sci. 2000;23(2):133-50.

7. Sloan AE, Dansey R, Zamorano L, Barger G, Hamm C, Diaz F, Baynes R, Wood G. Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes. Neurosurg Focus. 2000; 9(6):e9.

6. Araki K, Noguchi Y, Hirouchi T, Yoshikawa E, Kataoka S, Silverni L, Miyazawa H, Kuzuhara H, Suzuki C, Shimada Y, Hamasato S, Maeda N, Shimamura Y, Ogawa Y, Ohtsuki Y, Fujimoto S. Cancer regression induced by modified CTL therapy is regulated by HLA class II and class I antigens in Japanese patients with advanced cancer. Int J Oncol. 2000;17(6):1107-18.

5. Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence an 11-year follow-up study of a general population. Lancet. 2000 ;356(9244):1795-9.

4. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet. 2000 ;356(9232):802-7.

3. Kimura H, Yamaguchi Y. A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. Cancer. 1997;80(1):42-9.

2. Fujita K, Ikarashi H, Takakuwa K, Kodama S, Tokunaga A, Takahashi T, Tanaka K. Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes. Clin Cancer Res. 1995;1(5):501-7.

1. Gale RP, Butturini A. Transplants of blood-derived hematopoietic cells. Bone Marrow Transplant. 1990.